A review on the medicinal chemistry of sodium glucose co-transporter 2 inhibitors (SGLT2-I): Update from 2010 to present
Diabetes mellitus (DM) is one of the leading causes of death by World Health Organization in 2019 and is considered a significant cause of other diseases including heart attack, stroke, kidney failure, blindness, and lower limb amputation. Sodium glucose co-transporter 2 (SGLT2) is a protein that re...
Saved in:
Main Authors: | Jonali Ramani (Author), Harshil Shah (Author), Vivek K. Vyas (Author), Manmohan Sharma (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2022-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The metabolic model of heart failure: the role of sodium glucose co-transporter-2 (SGLT-2) inhibition
by: Muhammad Saad, et al.
Published: (2018) -
Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a growing class of anti-diabetic agents
by: Eva M Vivian
Published: (2014) -
Empagliflozin: a new sodium-glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes
by: Joshua J Neumiller
Published: (2014) -
Safety of sodium-glucose transporter 2 (SGLT-2) inhibitors in patients with type 2 diabetes: a meta-analysis of cohort studies
by: Chun Xing Li, et al.
Published: (2023) -
Sodium-glucose co-transporter-2 inhibitor (SGLT2i) treatment and risk of osteomyelitis: A pharmacovigilance study of the FAERS database
by: Hui Zhao, et al.
Published: (2023)